
Pharmacally
AML
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in AML
Clinical TrialsSELLAS Reports 57% Response Rate with SLS009 in TP53-Mutated AMLSELLAS reported Phase 2 findings for SLS009 combined with azacitidine and venetoclax in relapsed/refractory AML.Fact-Checked
Clinical TrialsOryzon Reports Positive Iadademstat Data in First-Line AMLOryzon Genomics reported updated Phase Ib ALICE-2 data showing iadademstat combined with azacitidine and venetoclax achieved a 100% overall response rate and a 78% complete response rate in…Fact-Checked
Clinical TrialsZiftomenib + 7+3 Achieves 94% One-Year Survival in NPM1-Mutant AML in KOMET-007 TrialPhase 1/2 KOMET‑007 results show ziftomenib plus 7+3 delivers high remission rates, deep molecular clearance, and durable survival in NPM1‑mutant and KMT2A‑rearranged AML.Fact-Checked
Health TidingsFDA Backs Cullinan Therapeutics’ CLN-049 With Orphan Drug Status in AMLCullinan Therapeutics announced that the FDA has granted Orphan Drug Designation to CLN‑049 for relapsed/refractory acute myeloid leukemia (AML).Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.